Company Description
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States.
The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.
It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells.
It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross.
The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024.
Renovaro Inc. is headquartered in Los Angeles, California.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Hon. Mark R. Dybul M.D. |
Contact Details
Address: Century City Medical Plaza, 2080 Century City East Suite 906 Los Angeles, California 90067 United States | |
| Phone | 45 39179840 |
| Website | renovarobio.com |
Stock Details
| Ticker Symbol | RENB |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001527728 |
| CUSIP Number | 236078101 |
| ISIN Number | US29350E1047 |
| Employer ID | 45-2259340 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Hon. Mark R. Dybul M.D. | Chief Executive Officer, Director and Member of HBV Scientific Advisory Board |
| Dr. Francois Binette M.Sc., Ph.D. | Chief Operating Officer and Executive Vice President for Research and Development |
| Dr. Serhat Gümrükcü | Co-Founder and Inventor |
| Simon Tarsh | Interim Chief Financial Officer |
| Greg Duczynski Ph.D. | Senior Vice President for Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 13, 2024 | 8-K | Current Report |
| Mar 7, 2024 | 8-K | Current Report |
| Mar 5, 2024 | 8-K | Current Report |
| Feb 23, 2024 | D | Notice of Exempt Offering of Securities |
| Feb 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 16, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 16, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 16, 2024 | 8-K | Current Report |
| Feb 14, 2024 | 10-Q | Quarterly Report |